GREY:IPHAF - Post by User
Post by
go4futureon Sep 09, 2009 10:13am
368 Views
Post# 16289368
More FDA Saftety Alerts (Cellcept/TNF Blockers)
More FDA Saftety Alerts (Cellcept/TNF Blockers)The FDA has recently mandated additional safety alert updates for TNF Blockers & Cellcept...
TNF Blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi): Increased risk of Lymphona & other cancers (Q&A added to clarify numbers reported and drug breakdowns reported. FDA states they believe numbers are underreported. (Aug 4 &31). The FDA has also identified new safety information related to the occurrence of leukemia and new-onset psoriasis in patients treated with TNF blockers.
https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm175843.htm
https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm180694.htm
Cellcept: Pure Red Cell Aplasia (PRCA), a type of anemia (Aug 14)
https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm177397.htm
As time goes by these drugs are piling up quite a few different types of black label warnings, regrdless they still seem to pull in big $$$ for major drug companies. Seems that the drug companies are shifting their marketing and drug testing (or new products) to RA for expanding sales potential where competition is less and risks more tolerated. If this is happenning, it should potentially expand the Psoriasis market for new drugs with less risk profiles with marketing advantages like Voclosporin.